Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 274


Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.

Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ.

J Neurosci. 2010 Aug 11;30(32):10624-38. doi: 10.1523/JNEUROSCI.0402-10.2010.


Dysregulation of mTOR signaling in fragile X syndrome.

Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin RS.

J Neurosci. 2010 Jan 13;30(2):694-702. doi: 10.1523/JNEUROSCI.3696-09.2010.


Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110β-selective inhibitor.

Gross C, Bassell GJ.

Mol Med. 2012 May 9;18:336-45. doi: 10.2119/molmed.2011.00363.


Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.

Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST.

Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15537-42. Epub 2007 Sep 19.


c-Jun N-terminal kinase regulates mGluR-dependent expression of post-synaptic FMRP target proteins.

Schmit TL, Dowell JA, Maes ME, Wilhelm M.

J Neurochem. 2013 Dec;127(6):772-81. doi: 10.1111/jnc.12453. Epub 2013 Oct 24.


Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Iliff AJ, Renoux AJ, Krans A, Usdin K, Sutton MA, Todd PK.

Hum Mol Genet. 2013 Mar 15;22(6):1180-92. doi: 10.1093/hmg/dds525. Epub 2012 Dec 18.


Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome.

Zhang L, Alger BE.

J Neurosci. 2010 Apr 21;30(16):5724-9. doi: 10.1523/JNEUROSCI.0795-10.2010.


Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation.

Nalavadi VC, Muddashetty RS, Gross C, Bassell GJ.

J Neurosci. 2012 Feb 22;32(8):2582-7. doi: 10.1523/JNEUROSCI.5057-11.2012.


Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.

Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM.

Sci Transl Med. 2012 Sep 19;4(152):152ra128.


Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.

Kumari D, Bhattacharya A, Nadel J, Moulton K, Zeak NM, Glicksman A, Dobkin C, Brick DJ, Schwartz PH, Smith CB, Klann E, Usdin K.

Hum Mutat. 2014 Dec;35(12):1485-94. doi: 10.1002/humu.22699.


Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2.

Gross C, Yao X, Pong DL, Jeromin A, Bassell GJ.

J Neurosci. 2011 Apr 13;31(15):5693-8. doi: 10.1523/JNEUROSCI.6661-10.2011.


Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.

Osterweil EK, Krueger DD, Reinhold K, Bear MF.

J Neurosci. 2010 Nov 17;30(46):15616-27. doi: 10.1523/JNEUROSCI.3888-10.2010.


BDNF in fragile X syndrome.

Castrén ML, Castrén E.

Neuropharmacology. 2014 Jan;76 Pt C:729-36. doi: 10.1016/j.neuropharm.2013.05.018. Epub 2013 May 29. Review.


Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse.

Ronesi JA, Huber KM.

Sci Signal. 2008 Feb 5;1(5):pe6. doi: 10.1126/stke.15pe6. Review.


Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Krueger DD, Bear MF.

Annu Rev Med. 2011;62:411-29. doi: 10.1146/annurev-med-061109-134644. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk